Despite the potential ERα-dependent effect of APN, patients with low leptin/APN ratios have shown a statistically longer cancer-specific survival for OC, which may show APN as a good candidate against DIO and derived metabolic diseases, including cancer [56]. This evidence concerns the gene ESR1 and cancer.